Related Experiment Video
Updated: Feb 23, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Impact of pharmacological spasm provocation test in patients with a history of syncope
1Department of Cardiology, Ehime Prefectural Niihama Hospital, Hongou 3 Choume 1-1, Niihama, Ehime, 792-0042, Japan. EZF03146@nifty.com.
Insights
Coronary artery spasm, a cause of cardiac issues, was found in 75% of syncope patients. This suggests investigating coronary artery spasm in patients experiencing syncope, even without chest pain.
Area of Science:
- Cardiology
- Vascular Medicine
Background:
- Coronary artery spasm contributes to various cardiac disorders.
- Syncope is a significant clinical symptom requiring etiological investigation.
Purpose of the Study:
- To investigate the prevalence and characteristics of coronary artery spasm in patients presenting with syncope.
- To determine if coronary artery spasm is a potential cause of syncope, particularly in the absence of typical chest symptoms.
Main Methods:
- Retrospective analysis of 5781 patients undergoing coronary angiography over 26 years.
- Pharmacological spasm provocation testing in 64 patients with a history of syncope.
- Evaluation of coronary artery spasm based on transient vessel narrowing and electrocardiographic changes.
Main Results:
- Out of 95 patients with syncope history, 64 underwent spasm testing.
- Positive spasm was observed in 48 patients, with definite coronary spastic angina (CSA) in 35 (54.7%).
- CSA was diagnosed in 75% of patients with syncope within one year, including 13 patients without chest symptoms.
Conclusions:
- Coronary artery spasm is a significant finding in patients with syncope.
- Coronary artery spasm should be considered as a potential cause of syncope, even in the absence of chest pain or pressure.
- Further investigation into coronary artery spasm is warranted for patients with a history of syncope.
Abstract:
Coronary artery spasm is involved in the pathogenesis of various cardiac disorders. We investigated patients with a history of syncope who underwent elective coronary angiography. We retrospectively analyzed 5781 consecutive patients who had diagnostic or follow-up angiography during a 26-year period. During this period, we found 95 patients with a history of syncope before elective coronary angiography. Pharmacological spasm provocation testing was performed in 64 patients with a history of syncope (<1 year). Positive pharmacological response was observed in 48 patients, while the remaining 16 patients had negative tests. Positive spasm was defined as a transient ≥90% narrowing with ischemic electrocardiographic changes. Among the 64 patients, definite coronary spastic angina (CSA) was found in 35 patients (54.7%) and suspected CSA was found in 13 patients (20.3%). Among the 35 patients with definite CSA, 22 patients (62.9%) had chest symptoms before syncope, but 13 (37.1%) had no chest symptom before syncope. No difference in clinical characteristics was observed between the two groups. Focal spasm during pharmacological spasm provocation tests was significantly higher in patients with chest symptoms than in those without chest symptoms before syncope (54.3 vs. 12.0%, p < 0.002). CSA was observed in 75.0% of patients with a history of syncope (<1 year). Thirteen patients with definite CSA had neither chest pain nor chest pressure before syncope. We should therefore investigate coronary artery spasm as a potential etiology in patients with a history of syncope.
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Depolarizing Blockers: Pharmocokinetics
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...

